

ARRAY BIOPHARMA INC
Form 8-K
June 07, 2010

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

June 5, 2010

Array BioPharma Inc.

(Exact name of registrant as specified in its charter)

Colorado

000-31979

84-1460811

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

3200 Walnut Street, Boulder, Colorado

80301

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(303) 381-6600

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Top of the Form

Item 8.01 Other Events.

On June 5, 2010, Array BioPharma Inc. issued a press release announcing that ARRY-520 is well tolerated and demonstrates preliminary activity as a single agent in multiple myeloma patients. The full text of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 - Press release dated June 5, 2010 entitled "ARRAY BIOPHARMA'S ARRY-520 WELL TOLERATED AND DEMONSTRATES PRELIMINARY ACTIVITY AS A SINGLE AGENT IN MULTIPLE MYELOMA PATIENTS."

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Array BioPharma Inc.

June 7, 2010

By: *R. Michael Carruthers*

*Name: R. Michael Carruthers
Title: Chief Financial Officer*

Top of the Form

Exhibit Index

| Exhibit No. | Description |
|--------------------|---|
| 99.1 | Press Release dated June 5, 2010 "ARRAY BIOPHARMA'S ARRAY-520 WELL TOLERATED AND DEMONSTRATES PRELIMINARY ACTIVITY AS A SINGLE AGENT IN MULTIPLE MYELOMA PATIENTS." |